Actavis UK (hydrocortisone tablets) (abuse of dominance)
Actavis UK (hydrocortisone tablets) (abuse of dominance)

The following Competition guidance note provides comprehensive and up to date legal information covering:

  • Actavis UK (hydrocortisone tablets) (abuse of dominance)
  • Case facts
  • Timeline
  • Commentary
  • Related cases

CASE HUB

See further, timeline, commentary and related cases.

Case facts

Outline CMA Article 102 TFEU/Chapter II investigation into Actavis UK in relation to an alleged abuse of dominance through charging excessive and unfair prices for hydrocortisone tablets.

Latest developments On 9 August 2017, the CMA issued a statement of objections to Intas Pharmaceuticals Limited and Accord Healthcare Limited. Intas and Accord now own Actavis UK and the CMA is proposing to find them jointly and severally liable for the alleged infringements from their period of ownership.

Parties Actavis UK is a pharmaceutical company, ultimately owned by Allergan plc, a US-based global pharmaceutical group. Actavis UK has now been rebranded as Accord Healthcare.

Actavis UK includes the following companies:
• from June 2008 to 31 October 2012–Auden Mckenzie (Pharma Division) Limited
• from 1 November 2012 to 28 May 2015–Auden Mckenzie (Pharma Division) Limited and Auden Mckenzie Holdings Limited
• from 29 May 2015 to 24 June 2016–Auden Mckenzie (Pharma Division) Limited, Auden Mckenzie Holdings Limited, Actavis UK Limited and Allergan plc.

Accord Healthcare Limited (Accord) is a acquired Actavis UK in January 2017. Accord is